is guiding for a 30–40% revenue growth this fiscal year, with profit after tax expected to expand at an even sharper 50–60% clip. This projection is based on a pipeline of 51 approved ANDAs, 30 of which are queued for commercial launch over the next six to eight quarters, alongside a strengthening CDMO order book and an emerging markets business that spans over 500 active registrations. Moreover, the company is also seeing traction in it's veterinary and government businesses, aided by a few national contracts secured on fixed-volume and fixed-price terms, which are expected to provide steady revenue visibility. Having a market cap of Rs 4,837 crore, the company has reported a strong sales growth of 162% CAGR and profit growth of 139% CAGR over the past 3 years. With this new projections, the company's sales and profits are expected to further grow in the coming years.

#FundamentalViews#WatchOutFor#StockInNews#MacroViews#Miscellaneous

1,158 likes·73 comments